Assembly Biosciences (ASMB) Q2 2025 earnings summary

Executive summary

• Focused on developing therapeutics for serious viral diseases, advancing four clinical candidates in 2025, and collaborating with Gilead Sciences.

• Pipeline includes helicase-primase inhibitors for genital herpes, an HDV entry inhibitor, a next-gen HBV capsid modulator, and a broad-spectrum NNPI for transplant-related herpesviruses.

• Reported positive interim and topline results for several Phase 1 studies, including hepatitis and herpes programs.

• Presented new clinical and preclinical data at major scientific conferences, highlighting HSV and HBV/HDV progress.

• Gilead collaboration provides funding, opt-in rights, milestone/royalty payments, and increased equity stake.

Financial highlights

• Collaboration revenue was $9.6M for Q2 2025, up 13% year-over-year; $19.0M for the six months, up 33%.

• Cash, cash equivalents, and marketable securities totaled $75.0M as of June 30, 2025, down from $91.0M at March 31, 2025.

• Net loss for Q2 2025 was $10.2M ($1.33/share), improved from $11.2M ($1.98/share) in Q2 2024.

• Research and development expenses for Q2 2025 were $16.1M, slightly down year-over-year due to lower ABI-6250 costs.

• Operating cash outflow was $40.2M for the first half of 2025, up from $35.5M in the prior year.

Outlook and guidance

• Cash runway projected to fund operations into mid-2026; substantial doubt exists about ability to continue beyond that without new funding.

• Plans to seek further funding through equity or collaboration payments; future capital needs depend on pipeline progress and Gilead outcomes.

• Proof-of-concept Phase 1b data for ABI-5366 and ABI-1179 in genital herpes expected by fall 2025.

• ABI-6250 preclinical data to be presented at the International HBV Meeting in September 2025.